Thus, in agreement with the central role for SNF2 enzymes and their CRC complexes in blood cell differentiation, mutations are often observed in patients with malignant lymphoma and AML, suggesting that disruptions in the function of these enzymes and complexes could contribute to these blood cancer phenotypes. Here, SMARCA2 is linked to hematopoietic and lymphoid system neoplasm.